FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.

Noboru NakaigawaKeiichi KondoTomohiro KanetaUkihide TateishiRyogo MinamimotoKazuhiro NamuraDaiki UenoKazuki KobayashiTakeshi KishidaIchiro IkedaHisashi HasumiKazuhide MakiyamaNarihiko HayashiKimito OsakaKentaro MuraokaKoji IzumiTakashi KawaharaJun-Ichi TeranishiYasuhide MiyoshiYasushi YumuraHiroji UemuraTomio InoueMasahiro Yao

Published in: Cancer chemotherapy and pharmacology (2018)

The max SUVmax by FDG PET/CT of patients with RCC evaluated after their first molecular targeted therapy predicts OS. FDG PET/CT is a useful "imaging biomarker" for patients with advanced RCC planning sequential molecular targeted therapies.

Keyphrases

renal cell carcinoma
high resolution
single molecule
mass spectrometry
fluorescence imaging